We claim:

~~1. A method of treating cancer in a patient in need thereof, comprising administering to said patient an antibody drug conjugate, wherein the cancer is follicular lymphoma (FL) that expresses CCR7, wherein the antibody drug conjugate comprises the formula~~

~~$Ab—(L—(D)_m)_n$~~

~~or a pharmaceutically acceptable salt thereof; wherein~~
~~Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;~~
~~L is a linker;~~
~~D is a drug moiety;~~
~~m is an integer from 1 to 8; and~~
~~n is an integer from 1 to 12.~~

~~2.~~1.A composition comprising an antibody drug conjugate for use in the treatment of cancer, wherein the cancer is follicular lymphoma (FL) that expresses CCR7, in a subject in need thereof, wherein the antibody drug conjugate comprises the formula

$Ab—(L—(D)_m)_n$

or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 12.

~~3.~~2.Use of an antibody drug conjugate in the manufacture of a ~~medication~~ medicament for the treatment of cancer in a subject in need thereof, wherein the cancer is follicular lymphoma (FL) that expresses CCR7, wherein the antibody drug conjugate comprises the formula

$$Ab—(L—(D)_m)_n$$

or a pharmaceutically acceptable salt thereof; wherein

Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;

L is a linker;

D is a drug moiety;

m is an integer from 1 to 8; and

n is an integer from 1 to 12.

~~4. Use of an antibody drug conjugate for treating of cancer in a subject in need thereof, wherein the cancer is follicular lymphoma (FL) that expresses CCR7, wherein the antibody drug conjugate comprises the formula~~

$$~~Ab—(L—(D)_m)_n~~$$

~~or a pharmaceutically acceptable salt thereof; wherein~~

~~Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;~~

~~L is a linker;~~


~~D is a drug moiety;~~

~~m is an integer from 1 to 8; and~~

~~n is an integer from 1 to 12.~~

~~5.~~3. The ~~method,~~ composition for use of claim 1, or the use of ~~any one of~~ claim~~s~~ ~~1-4~~2, wherein the cancer is relapsed or refractory follicular lymphoma.

~~6.~~4. The ~~method,~~ composition for use of claim 1 or claim 3, or the use of ~~any one of~~ claim~~s~~ ~~1-5~~2 or claim 3, where in the antibody drug conjugate comprises the following formula:



wherein n is about 3 to about 4, and Ab is an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a light chain comprising the amino acid sequence of SEQ ID NO:63; or a pharmaceutically acceptable salt thereof.

~~7.~~5. The ~~method,~~ composition for use of any one of claims 1, or 3-4, or the use of any one of claims ~~1~~2-~~6~~4, where in the antibody drug conjugate is in a non-salt form.

~~8.~~6. The ~~method,~~ composition for use of any one of claims 1, or 3-5, or the use of any one of claims ~~1~~2-~~7~~5, wherein the antibody drug conjugate or composition ~~are~~ is to be administered to the patient in combination with one or more additional therapeutic compounds.

~~9.~~7. The ~~method,~~ composition for use or the use of claim ~~8~~6, wherein the one or more additional therapeutic compounds is selected from a standard of care chemotherapeutic, a costimulatory molecule, or a checkpoint inhibitor.

~~10.~~8. The ~~method,~~ composition for use or the use of claim ~~9~~7, wherein the costimulatory molecule is selected from an agonist of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, STING, or CD83 ligand.

~~11.~~9. The ~~method,~~ composition for use or the use of claim ~~9~~7, wherein the checkpoint inhibitor is selected from an inhibitor of PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and/or TGFR beta.

~~12. A method of treating or preventing cancer in a subject in need thereof, comprising administering to said subject an antibody drug conjugate, wherein the cancer expresses CCR7, wherein the antibody drug conjugate comprises the formula~~

~~Ab—(L—(D)$_m$)$_n$~~

~~or a pharmaceutically acceptable salt thereof; wherein~~
~~Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;~~
~~L is a linker;~~
~~D is a drug moiety;~~
~~m is an integer from 1 to 8; and~~
~~n is an integer from 1 to 12,~~

~~wherein the antibody drug conjugate is administered to said subject at about 0.1 mg/kg to about 10 mg/kg.~~

~~13.~~10. A composition comprising an antibody drug conjugate for use in the treatment of cancer, wherein the cancer expresses CCR7, in a subject in need thereof, wherein the antibody drug conjugate comprises the formula

Ab—(L—(D)$_m$)$_n$

or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 12,

wherein the antibody drug conjugate is to be administered to said subject at about 0.1 mg/kg to about 10 mg/kg.

~~14.~~11. Use of an antibody drug conjugate in the manufacture of a ~~medication~~ medicament for the treatment of cancer in a subject in need thereof, wherein the cancer expresses CCR7, wherein the antibody drug conjugate comprises the formula

$$Ab—(L—(D)_m)_n$$


or a pharmaceutically acceptable salt thereof; wherein
Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;
L is a linker;
D is a drug moiety;
m is an integer from 1 to 8; and
n is an integer from 1 to 12,
wherein the antibody drug conjugate is to be administered to said subject at about 0.1 mg/kg to about 10 mg/kg.

~~15. Use of an antibody drug conjugate for treating of cancer in a subject in need thereof, wherein the cancer expresses CCR7, wherein the antibody drug conjugate comprises the formula~~

~~$$Ab—(L—(D)_m)_n$$~~

~~or a pharmaceutically acceptable salt thereof; wherein~~
~~Ab is an antibody or antigen binding fragment thereof that binds human CCR7 protein;~~
~~L is a linker;~~
~~D is a drug moiety;~~
~~m is an integer from 1 to 8; and~~
~~n is an integer from 1 to 12,~~
~~wherein the antibody drug conjugate is administered to said subject at about 0.1 mg/kg to about 10 mg/kg.~~

~~16.~~12. The ~~method,~~ composition for use of claim 10 or the use of ~~any one of~~ claim~~s~~ ~~12-15~~11, where in the antibody drug conjugate comprises the following formula:



Ab-MPET-DM4

wherein n is about 3 to about 4, and Ab is an antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a light chain comprising the amino acid sequence of SEQ ID NO:63; or a pharmaceutically acceptable salt thereof.

~~17.~~13. The ~~method,~~ composition for use of claim 10 or claim 12, or the use of ~~any one of~~ claims ~~12~~11 or claim 12~~-16~~, where in the antibody drug conjugate is in a non-salt form.

~~18.~~14. The ~~method,~~ composition for use of any one of claims 10, or 12-13, or the use of any one of claims ~~12~~11~~-17~~13, wherein the cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), peripheral T cell lymphomas (PTCL) such as adult T-cell leukemia/lymphoma (ATLL) and anaplastic large-cell lymphoma (ALCL), Non-Hodgkin's lymphoma (NHL) such as mantle cell lymphoma (MCL), Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL), and non-small cell lung cancer.

~~19.~~15. The ~~method,~~ composition for use of any one of claims 10, or 12-14, or the use of any one of claims ~~12~~11~~-18~~14, wherein the cancer is a relapsed or refractory cancer.

~~20.~~16. The ~~method,~~ composition for use of any one of claims 10, or 12-15, or the use of any one of claims ~~12~~11~~-19~~15, wherein the antibody drug conjugate is to be administered to the subject about once every 3 weeks.

~~21.~~17. The ~~method,~~ composition for use of any one of claims 10, or 12-16, or the use of any one of claims ~~12~~11 ~~20~~16, wherein the subject is to be treated for 1 cycle, 2 cycles, 3 cycles, 4 cycles, or 5 cycles.

~~22.~~18. The ~~method,~~ composition for use of any one of claims 10, or 12-17, or the use of any one of claims ~~12~~11 ~~21~~17, wherein the antibody drug conjugate is to be administered to the subject intravenously.